Report #2841867

Received May 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: CO
Recovered: Recovered
Vaccinated: May 1, 2025
Onset: May 2, 2025
Days to onset: 1
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	UNK	UNK	—

Symptoms (2)

FatigueNausea

Symptom narrative

Generalized symptoms. Extreme tiredness; Generalized symptoms nausea; This non-serious case was reported by a other health professional via sales rep and described the occurrence of tiredness in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 01-MAY-2025, the patient received Shingrix. On 02-MAY-2025, 1 days after receiving Shingrix, the patient experienced tiredness (Verbatim: Generalized symptoms. Extreme tiredness) and nausea (Verbatim: Generalized symptoms nausea). On 04-MAY-2025, the outcome of the tiredness was resolved and the outcome of the nausea was resolved (duration 2 days). It was unknown if the reporter considered the tiredness and nausea to be related to Shingrix. It was unknown if the company considered the tiredness and nausea to be related to Shingrix. Additional Information: GSK Receipt Date: 05-MAY-2025 The patient had generalized symptoms extreme tiredness and nausea after Shingrix vaccination.